The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 annual meeting, held in Bogotá, Colombia, featured soapbox presentations highlighting innovative approaches to psoriatic disease (PsD) care. Dr. Vasileios Charisis presented the Psoriatic Arthritis Inflammation Explained Through Multi-Source Data Analysis Guiding a Novel Personalised Digital Care Ecosystem (iPROLEPSIS) project, which applies digital phenotyping and explainable artificial intelligence to monitor psoriatic arthritis (PsA) using smartphone-based typing dynamics and hand motion tracking. Pilot data demonstrated high accuracy in detecting functional impairments, underscoring the potential of digital biomarkers for personalized disease management. Dr. Rodrigo García-Salinas reported consensus recommendations from the Red de Excelenciaen Artritis para la América Latina–Pan American League of Associations for Rheumatology (REAL-PANLAR) group to establish PsD Centers of Excellence (CoEs) in Latin America. Through a Delphi process, experts from 12 countries defined structural, process, and outcome standards, resulting in 2 adaptable models—optimal and model—designed to reduce diagnostic delays, enhance multidisciplinary collaboration, and improve outcomes. Dr. Juan Raul Castro-Ayarza summarized real-world evidence on biologic drug survival in Latin America, emphasizing fragmented data and variability across national cohorts. Findings from Venezuela, Brazil, Argentina, and Colombia revealed differences in treatment persistence and predictors of discontinuation, reinforcing the need for a standardized regional registry. Collectively, these initiatives demonstrate the value of digital health tools, region-specific care frameworks, and real-world evidence in advancing PsD management globally.
Colaco et al. (2026) studied this question.